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ABSTRACT
Cataract is one of the earliest secondary complications of diabetes mellitus. The lens is a closed system with limited capability to repair 
or regenerate itself. Current evidence supports the view that cataractogenesis is a multifactorial process. Mechanisms related to glu-
cose toxicity, namely oxidative stress, processes of non-enzymatic glycation and enhanced polyol pathway significantly contribute to 
the development of eye lens opacity under conditions of diabetes. There is an urgent need for inexpensive, non-surgical approaches 
to the treatment of cataract. Recently, considerable attention has been devoted to the search for phytochemical therapeutics. Several 
pharmacological actions of natural flavonoids may operate in the prevention of cataract since flavonoids are capable of affecting mul-
tiple mechanisms or etiological factors responsible for the development of diabetic cataract. In the present paper, natural flavonoids 
are reviewed as potential agents that could reduce the risk of cataract formation via affecting multiple pathways pertinent to eye lens 
opacification. In addition, the bioavailability of flavonoids for the lens is considered. 
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by which glucose exerts its toxicity is of utmost impor-
tance for rational pharmacological interventions to treat 
diabetic cataract. The etiology of diabetic cataract is 
multifactorial; multiple hyperglycemia-dependent mech-
anisms leading to an array of subtle post-translational 
modifications in the lens structural proteins contribute to 
its development. The lens is a closed system with limited 
capability to repair or regenerate itself. The proteins of 
the lens are extremely long-lived and there is virtually no 
protein turnover, which provides great opportunities for 
post-translational modification to occur (Bron et al., 2000; 
Harding, 2002; Krishna Sharma & Santhoshkumar, 2009). 
Oxidative stress and its sequelae are clearly involved in 
the etiology of senile cataract, while mechanisms related 
to glucose toxicity, namely oxidative stress, enhanced 
polyol pathway, and processes of non-enzymatic glyca-
tion, significantly contribute to the development of eye 
complications in diabetic patients (Baynes & Thorpe, 
1999; Kyselova et al., 2004; Brownlee, 2005; DelCorso et 
al., 2008; Alexiou et al., 2009; Obrosova et al., 2010).
Under conditions of diabetes, the need of tight blood 
glucose control is a key prerequisite to reduce the inci-
dence, progression, and severity of cataract. Yet periods 
of hyperglycemia in the daily regimen of a diabetic patient 
Introduction
Diabetic patients are susceptible to the development of 
chronic health complications responsible for a significant 
increase in their morbidity and mortality. Cataract, 
eye lens opacification, is one of the earliest secondary 
complications of diabetes mellitus (Kyselova et al., 2004; 
Obrosova et al., 2010). Diabetic patients are about 60% 
more likely to develop these eye conditions. People with 
diabetes also tend to get cataract at a younger age with a 
faster progression (Bron et al., 1998). 
The association between diabetes and cataract forma-
tion has been shown in clinical epidemiological and basic 
research studies (Bron et al., 1998; Pollreisz and Schmidt-
Erfurth, 2010; Obrosova et al., 2010). Since extracellular 
glucose diffuses into the lens uncontrolled by the hormone 
insulin, the lens is one of the most affected body parts 
in diabetes mellitus. The understanding of mechanisms 
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cannot be avoided, with all of the aforementioned delete-
rious consequences of glucose toxicity. Therefore addi-
tional adjunct therapy interfering with the pathological 
processes at molecular level, e.g. based on antioxidants, 
aldose reductase inhibitors and anti-glycation agents, is 
needed to attenuate the noxious effects of glucose. 
I n n o v a t i v e  s t r a t e g i e s  i n  t r e a t m e n t  o f  d i s e a s e s  o f  
multifactorial origin are oriented on a rational design of 
chemical entities able to affect simultaneously multiple 
key mechanisms involved. This approach increases the 
chance of successful therapeutic intervention, decreases 
the risk of side effects and is economical. An example of 
the "multi-target" strategy in treatment of diabetic com-
plications are the bifunctional compounds combining the 
aldose reductase inhibiory activity with the antioxidant 
effect, including pyrido-pyrimidines (La Motta et al., 
2007), pyridazines (Coudert et al., 1994), benzopyranes 
(Constantino et al., 1999) and carboxymethylated pyri-
doindoles (Stefek et al., 2008) or compounds combining 
the aldose reductase inhibiory activity with the ability 
to attenuate nonenzymatic glycation (Demopoulos et 
al., 2005). Considering the detoxification role of aldose 
reductase against toxic carbonyl products, significantly 
enhanced in diabetic tissues (Baynes, 1991; Thorpe & 
Baynes, 1996; Thornalley, 2005; Turk, 2010), the concur-
rent antioxidant action of a multifunctional drug can 
counterbalance its inhibition. In addition, antioxidant 
activity may suppress processes of advanced glycation 
(glycoxidation) at the level of free radical intermediates 
(Baynes, 1991; Thorpe & Baynes, 1996; Brownlee, 2000; 
Giacco & Brownlee, 2010).
Recently, considerable attention has been devoted to 
the search for phytochemical therapeutics. There is epide-
miologic evidence that a sufficient intake of fruit and veg-
etables can lower the risk of cataract in humans (Taylor, 
1993; 1999). A variety of constituents, like vitamins, 
minerals, fiber, and numerous phytochemicals, includ-
ing flavonoids may contribute to the protective effect of 
fruits and vegetables. Indeed, several pharmacological 
actions of flavonoids may operate in the prevention of 
both age-related and diabetic cataract since flavonoids are 
capable of affecting multiple mechanisms or etiological 
factors responsible for the development of sight threaten-
ing ocular diseases (Bhimanagouda, 2009; Majumdar et 
al., 2010; Kalt et al. 2010)
At the pre-clinical level of animal models, flavonoids 
(Figure 1) have been shown to be protective against eye 
lens opacification. In the present paper, flavonoids are 
reviewed as potential agents that could reduce the risk 
of cataract formation via affecting multiple key pathways 
pertinent to eye lens opacification, including oxidative 
stress, non-enzymatic glycation and polyol pathway. In 
addition, the bioavailability of flavonoids to the lens is 
considered.
Anticataract action of fl  avonoids
Models in vitro
Under in vitro conditions, using rat lens organ culture 
endowed with hydrogen peroxide, low micromolar 
levels of flavonol quercetin inhibited oxidation-induced 
sodium and calcium influx and loss of lens transpar-
ency (Sanderson et al., 1999). As shown later by Cornish 
et al. (2002), quercetin was rapidly lost from the media 
and readily entered the lens where it was methylated to 
3´-O-methyl quercetin. Both quercetin and its metabolite 
were active in inhibiting oxidative damage in the lens. 
The glucoside of isorhamnetin (methylated querce-
tin), isolated as a bioactive flavonoid from the leaves of 
Cochlospermum religiosum (Gayathri et al., 2010) and 
flavonoid fraction isolated from fresh leaves of Vitex 
negundo (Rooban et al., 2011) protected enucleated rat 
eye lenses against selenite-induced cataract in an in vitro 
culture model.
The flavonoid venoruton, a mixture of mono-, di-, 
tri- and tetrahydroxyethylrutosides, significantly reduced 
the degree of opacification and the leakage of lactate dehy-
drogenase in rat lens organ culture simulating diabetic 
conditions (Kilic et al., 1997). 
Animal models in vivo
As early as in 1977, Varma et al. (1977) studied the effect 
of quercetin rhamnoside (quercitrin) on the development 
of cataract in the rodent Octodon degus made diabetic by 
a single intraperitoneal dose of streptozotocin. The con-
trol diabetic animals not receiving quercitrin developed 
nuclear opacity by about the tenth day after the onset of 
hyperglycemia. In contrast, the diabetic animals treated 
with quercitrin did not develop cataracts even 25 days 
after the onset of diabetes, although they had a blood glu-
cose concentration similar to that of the control diabetic 
group. In a similar study performed by Lu et al. (2008) in 
streptozotocin diabetic rats, high-isoflavone soy protein 
markedly decreased the death rate and incidence of cata-
racts in the diabetic animals. At the same time, reduced 
serum glucose and methylglyoxal were recorded in the 
treated rats. Nakano et al. (2008) reported lower incidence 
of cataract in streptozotocin diabetic rats treated with 
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Figure 1. Basic fl  avonoid structure.71
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flavangenol, a complex mixture of bioflavaonoids with 
oligomeric proanthocyanidin as main constituents.
Topical administration of quercetin to the orbital 
pouch of the galactosemic neonatal rat diminished 
cataractogenesis in the corresponding lens. Comparison 
with the contralateral lens indicated that quercetin 
reduced intracellular edema, prevented extracellular fluid 
accumulation and maintained cellular interdigitation 
of the superficial anterior cortical fiber. In addition to 
preserving fiber integrity, topical application of quercetin 
maintained lens growth as evidenced by radius and dry 
weight measurements (Beyer-Meyers & Farnsworth, 
1979). Analogically, in the same galactosemic rat model, 
Mohan  et al. ( 1 9 8 8 )  r e c o r d e d  a n t i c a t a r a c t  a c t i o n  o f  
quercetin and structurally related myricetin after topical 
administration. In galactosemic rats, oral treatment with 
quercetin resulted in a significant correction of eye lens 
electrolyte disturbances and normalization of lens pro-
tein levels (Ramana et al., 2007). The results imply that 
inclusion of quercetin contributes to lens transparency 
through the maintenance of characteristic osmotic ion 
equilibrium and protein levels of the lens. The isoflavone 
genistein delayed the progression of cataracts induced in 
rats by dietary galactose (Huang et al., 2007).
The rat selenite cataract model (Shearer et al., 1997; 
Ghupta et al., 2009; Kyselova, 2010) was extensively used 
to study the anticataract action of flavonoids. The results 
of Orhan et al. (1999) showed that ethanol extract of prop-
olis, rich in flavonoids (Scheller et al., 1990), and quercetin 
prevented cataract formation to the extent of 70 and 
40%, respectively. Standardized extract of Ginkgo biloba 
(Egb761) did not affect cataract formation. The flavonoid 
fraction from Emilia sonchifolia was reported (Lija et al., 
2006) to decrease the rate of maturation of selenite cata-
ract more efficiently than quercetin. Activities of super-
oxide dismutase, catalase and reduced glutathione were 
found to be increased in the group treated with Emilia 
sonchifolia, while thiobarbituric acid reacting substances 
were decreased compared with the selenite induced group. 
Rutin (quercetin rutinoside) was reported (Isai et al., 
2009) to prevent selenite-induced cataractogenesis in 
rat pups. At the end of a 30-day study period, all the rat 
pups that had received only selenite were found to have 
developed a dense nuclear opacity in the lens of each eye, 
whereas only 33.3% of pups that had received selenite and 
been treated with an intraperitoneal dose (175 mg/kg of 
body weight) of rutin hydrate were found to have mild len-
ticular opacification in each eye. The other 66.7% of pups 
in that group had clear lenses in both eyes, as in normal 
pups. The mean activities of catalase, superoxide dis-
mutase, glutathione peroxidase, glutathione transferase, 
and glutathione reductase were found to be significantly 
lower in the lenses of cataract-untreated rat pups than in 
normal control rat lenses. However, in lenses treated with 
rutin hydrate, the mean activities of antioxidant enzymes 
were significantly higher than the values in rat pups with 
untreated cataracts.
Onion is a flavonoid-rich foodstuff and the major 
flavonoids contained have been identified as quercetin, 
quercetin-4‘-glucoside and quercetin-3,4‘-diglucoside 
(Fossen et al., 1998; Miean and Mohamed, 2001). In the 
study of Javadzadeh et al. (2009), the instillation of fresh 
juice of crude onion into the rat eyes was found to prevent 
selenite-induced cataract formation by 75%. This effect 
was associated with higher mean total antioxidant level 
as well as higher mean activities of superoxide dismutase 
and glutathione peroxidase in the lenses of rats receiving 
fresh juice of crude onion and subcutaneous injection 
of sodium-selenite, compared with those rats which 
received only sodium-selenite injection. The onion juice, 
as a flavonoid-rich source, was postulated to provide an 
additional support to the antioxidant agents, leading to 
the elevation of total antioxidant levels and superoxide 
dismutase and glutathione peroxidase activities in the rat 
lens, in spite of exposure to sodium-selenite.
Flavonoid fractions isolated from natural sources 
including green and black tea (Thiagarajan et al., 2001; 
Gupta et al., 2002), Ginkgo biloba (Thiagarajan, 2002), 
grape seeds (Durukan et al., 2006), Emilia sonchifolia 
(Lija et al., 2006), Vitex negundo (Rooban et al. 2009) and 
broccoli (Vibin et al., 2010) were shown to have anticata-
ract activity in selenite-induced experimental cataract in 
rats. In addition, Ginkgo biloba extracts were found to 
protect rats against radiation-induced cataract (Ertekin 
et al., 2004).
Among others, damage to the lens epithelium is con-
sidered a possible cause of cataract formation (Hightower, 
1995). Catechin was found to inhibit apoptotic cell death 
in the lens epithelium of rats after cataract induction with 
N-methyl-N-nitrosourea (Leed et al., 2010). Grape seed 
extract rich in flavonoids reduced hydrogen-peroxide-
induced apoptosis of human lens epithelial cells and 
depressed H2O2-induced activation and translocation of 
NF-кB (Jia et al., 2011). Similarly, the flavonoid fisetin was 
found to protect human lens epithelial cells from UVB-
induced oxidative stress by inhibiting the generation of 
reactive oxygen species and modulating the activation of 
NF-кB and MAPK pathways (Yao et al., 2008).
Flavonoids as multifunctional agents
As reviewed below, flavonoids efficiently affect the mul-
tiple key molecular mechanisms involved in the etiology 
of both age-related and diabetic cataract, namely oxida-
tive stress, non-enzymatic glycation and polyol pathway. 
Structural requirements of flavonoids for efficient inhibi-
tion of the above mentioned processes are summarized. 
Flavonoids may interfere also with lens calpain proteases 
and lens epithelial cell signaling, which is however outside 
the scope of this review. 
Antioxidant action of ﬂ  avonoids
The antioxidant action of flavonoids, the best described 
biological activity of this group of natural polyphenolic 
substances, is covered by a number of excellent reviews 
(Bors et al., 1990; Cao et al., 1997; Pietta, 2000; Rice-
Evans, 2001; Nijveldt et al., 2001; Bors & Michel, 2002; 72
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Heim et al., 2002; Williams et al., 2004; Amič et al., 2007; 
Bischoff, 2008; Boots et al., 2008). Flavonoids may exert 
antioxidant effects due to their ability to act as free radical 
scavengers, hydrogen donating compounds, singlet oxygen 
quenchers, and metal ion chelators. Within the flavonoid 
family, quercetin is the most potent scavenger of reactive 
oxygen species, including superoxide, peroxyl, alkoxyl 
and hydroxyl radicals, and reactive nitrogen species like 
NO. and ONOO (Pietta, 2000; Butkovič et al., 2004; Amič 
et al., 2007; Boots et al., 2008). It is beyond the scope of 
this review to give a thorough survey of the abundant 
literature covering numerous studies of the antioxidant 
action of flavonoids. Nevertheless, key structural features 
responsible for the high antioxidant efficacy of flavonoids, 
also with relevance to the eye lens, are highlighted. 
The general structural requirements for effective 
radical scavenging and/or the antioxidant potential of fla-
vonoids are known as Bors’ criteria (Bors & Michel, 2002; 
Amič et al., 2007), namely (i) the presence of a catechol 
group in ring B, capable of readily donating hydrogen 
(electron) to stabilize a radical species, (ii) the presence of 
2,3-unsaturation in conjugation with a 4-oxo-function in 
the C-ring, which is responsible for electron delocalization, 
and (iii) the presence of a 3-hydroxyl group in the hetero-
cyclic ring which increases the radical-scavenging activ-
ity. The catechol moiety may also contribute to an ability 
to chelate transition metal ions, such as copper and iron. 
Fla v on oids w ere f oun d also to sca v eng e efficien tly  
the model free radicals of 2,2-diphenyl-1-picrylhydrazyl 
and α,γ-bisdiphenylene-β-phenylallyl (Butkovič et al., 
2004). Flavonoid chelating activity for transition metal 
ions has been well documented (Nijveldt et al. 2001; 
Pietta, 2000;Williams et al., 2004). Flavonoids inhibit 
xanthine oxidase, the enzyme responsible for superoxide 
anion production (Hamasaki et al., 1994). Interestingly, 
isorhamnetin (3-methylquercetin) was found to inhibit 
xanthine oxidase, even more efficiently than the aglycone 
form of quercetin (Nagao et al., 1999). 
As reviewed below, the high antioxidant efficacy 
of flavonoids is accompanied by their ability to inhibit 
aldose reductase and non-enzymatic glycation – activities 
of high relevance to the development of diabetic cataract.
Aldose reductase inhibition by ﬂ  avonoids
The accumulation of polyol sorbitol within the lens is a 
primary contributing factor to the formation of diabetic 
cataract (Yabe-Nishimura, 1998; Del Corso et al., 2008; 
Alexiou et al., 2009; Obrosova, 2010), a mechanism dif-
ferent from senile cataract. In diabetes, glucose is in a 
high concentration in the aqueous humor and can diffuse 
passively into the lens. The enzyme aldose reductase 
within the lens converts glucose to sorbitol. This polyol 
cannot diffuse passively out of the lens and accumulates 
or is converted to fructose. 
Aldose reductase inhibitors represent a potential ther-
apeutic strategy for preventing the onset or progression 
of diabetic cataract (Costantino et al., 2000; Miyamoto, 
2002; Suzen et al. 2003; Alexiou et al., 2009; Obrosova, 
2010). Pharmacophoric requirements for aldose reductase 
inhibitors are determined by the structural features 
of the inhibitor binding site of aldose reductase, which 
was shown to be formed by a large hydrophobic pocket 
(El-Kabbani et al., 2004). This pocket is mainly composed 
of two regions: a hydrophilic anionic binding site which 
accommodates acidic functionalities and a region of 
hydrophobic residues that binds the hydrophobic aro-
matic ring system of the inhibitors. Inhibitor binding is 
therefore a consequence of polar and non-polar interac-
tions between the inhibitor and the complementary 
residues that line the enzyme binding pocket. It has been 
proposed that the specificity for the inhibitor was mainly 
due to inhibitor-enzyme interactions at the non-polar 
domain (El-Kabbani & Podjarny, 2007).
To date, two main classes of active aldose reductase 
inhibitors have been reported and classified on the basis 
of the ionizable group which allows them to anchor to the 
catalytic site: carboxylic acids (substitution derivatives 
of acetic acid) and spirohydantoins, with epalrestat and 
sorbinil being the most representative members of each 
respective family (Costantino et al., 2000; Miyamoto, 
2002; Suzen et al. 2003; Alexiou et al., 2009). They are 
generally referred to as carboxylate-type and hydantoin-
type inhibitors. A third class of aldose reductase inhibi-
tors represents flavonoids. Since the mid-1970s, a number 
of studies have been reported on the inhibition of aldose 
reductase by flavonoids (Varma et al., 1975; Varma and 
Kinoshita, 1976; Okuda et al., 1982; Nakai et al., 1985; 
Lim et al., 2001; Jung et al., 2002; Matsuda et al., 2002; 
Kawanishi et al., 2003; Lee et al., 2010). Structural features 
required for a firm anchoring to the catalytic site of the 
aldose reductase enzyme, were summarized by Matsuda 
et al. (2002) as follows: (i) the presence of a 7-hydroxyl 
group and catechol moiety at the B ring guarantees the 
strong activity; (ii) the 5-hydroxyl moiety does not affect 
the activity; (iii) the 3-hydroxyl and 7-O-glucosyl moieties 
reduce the activity; (iv) the 2–3 double bond enhances 
the activity; (v) the flavonols having the catechol moiety 
(the 3´,4´-dihydroxyl moiety) at the B ring exhibit stron-
ger activity than those with the pyrogallol moiety (the 
3´,4´,5´-trihydroxyl moiety).
Inhibitory action of active flavonoid components 
isolated from natural products against rat lens or 
human recombinant aldose reductase were reported, 
often in comparison with quercetin used as a positive 
control (Matsuda et al., 2002; Suryanarayana et al., 2004; 
Wirasathien et al., 2007; Chethan et al., 2008; Carbone et 
al., 2009; Jung et al., 2008a,b, 2009; 2011; Lee et al., 2010). 
Aldose reductase inhibitors of the flavonoid class, in 
contrast to those of the carboxylate type whose acidic 
nature results in poor biological availability, possess a 
higher pKa value, which is a prerequisite for their better 
pharmacokinetics. 
In the light of the above mentioned biological activi-
ties of natural flavonoids, they serve as an example of 
bifunctional agents for the "multi-target" approach to the 
treatment of diabetic cataract by combining the aldose 
reductase inhibitory activity with its antioxidant action. 
In addition, starting from the flavonol quercetin as a lead 73
Also available online on PubMed Central
Interdisciplinary Toxicology. 2011; Vol. 4(2): 69–77
Copyright © 2011 Slovak Toxicology Society SETOX
structure, a series of 4H-1-benzopyran-4-one derivatives 
was designed and developed as semi-synthetic agents, 
with dual antioxidant/ aldose reductase inhibition activ-
ity (Costantino et al., 1999).
Advanced glycation inhibition by ﬂ  avonoids
The process of non-enzymatic glycation is well known to 
be one of the key mechanisms leading to diabetic cataract 
(Shamsi et al., 2000; Brownlee, 2001, 2005; Stitt, 2005; 
Monnier et al. 2005; Nagaraj et al., 2010). In compliance 
with the glycation theory of aging (Monnier & Cerami, 
1981), accumulation of advanced glycation endproducts in 
the aging lens, yet to a lesser extent in comparison with the 
diabetic eye, may contribute to age-related lens opacity. 
In seeking potential anti-cataract drugs, clinically useful 
anti-glycation agents are a reasonable option. As reviewed 
below, a number of naturally occurring flavonoids were 
reported to exhibit inhibitory effects on advanced glyca-
tion endproducts formation. 
Four flavonoids of the methanol extract of Thymus 
vulgaris, quercetin, eriodictyol, 5,6,4’-trihydroxy-7,8,3’-
trimethoxyflavone, and cirsilineol suppressed the levels 
of advanced glycation end products and fructosamines 
of bovine serum albumin under in vitro conditions 
(Morimitsu  et al., 1995). By using the bovine serum 
albumin glycation model, Beaulieu et al. (2010) demon-
strated that the flavonoid components of the Vaccinium 
vitis-idaea berry extract were potent antiglycation agents, 
while Wu et al.(2005) recorded significant inhibitory 
activity of the natural flavonoids luteolin, quercetin, 
and rutin. Rutin and metabolites of rutin were found 
to inhibit glycation product formation, including both 
fluorescent and nonfluorescent AGEs, induced by glu-
cose in collagen I in vitro (Cervantes-Laurean, 2006). 
Flavonoids markedly reduced pentosidine formation in 
collagen from bovine Achilles tendon incubated with 
glucose in vitro in the following decreasing order of their 
specific inhibitory activity: myricetin ≥ quercetin> rutin 
> (+)catechin > kaempferol (Urios et al., 2007). Rutin 
and its metabolites 3,4-dihydroxyphenylacetic acid and 
3,4-dihydroxytoluene were found to inhibit histone H1 
glycation by the powerful glycating agent ADP-ribose, as 
effectively as did aminoguanidine (Pashikanti et al., 2010). 
Rutin and G-rutin, a water soluble glucose derivative of 
rutin, suppressed glycation of muscle and kidney proteins 
exposed to glucose in vitro (Nagasawa et al., 2003a). 
Under in vivo conditions, G-rutin was found to inhibit 
glycation reactions in muscle, kidney and plasma proteins 
of streptozotocin-induced diabetic rats (Nagasawa et al., 
2003b).
In their study based on 62 flavonoids, Matsuda et al. 
(2003) formulated structural requirements of flavonoids 
for inhibition of protein non-enzymatic glycation: (i) as 
the hydroxyl groups at the 3´-, 4´-, 5-, and 7-positions 
increased in number, the inhibitory activities became 
stronger; (ii) the activities of flavones were stronger than 
those of corresponding flavonols, flavanones, and isofla-
vones; (iii) methylation or glucosylation of the 4´-hydroxyl 
group of flavones, flavonols, and flavanones reduced 
their activity; (iv) methylation or glycosylation of the 
3-hydroxyl group of flavonols tended to increase activity; 
(v) glycosylation of the 7-hydroxyl group of flavones and 
isoflavones reduced their activity. Yet these principles 
should be further corroborated. 
In seeking more efficient multifunctional flavonoids 
combining antioxidant activity with both aldose reduc-
tase and advanced glycation inhibitory action, for poten-
tial pharmacological prevention of diabetic cataract and 
other long-term diabetic complications, all three sets of 
the aforementioned criteria should be applied in screen-
ing available databases of flavonoid structures. 
Bioavailability of fl  avonoids
Biological activity of flavonoids is often assessed by using 
in vitro models; in almost all such studies, cells are treated 
with aglycones and data are reported at concentrations 
that elicited a response. However, plasma and tissues are 
not exposed in vivo to flavonoids in these forms. The 
forms reaching the blood and tissues are, in general, 
neither aglycones nor the same as the dietary source 
glycosides. In blood, flavonoids are present as conjugates 
of glucuronate or sulfate, with or without methylation 
of the catechol functional group. As a consequence, the 
flavonoid conjugates are likely to possess different biologi-
cal properties and distribution patterns within tissues and 
cells than have flavonoid aglycones. Although deconjuga-
tion can potentially occur in vivo to produce aglycone, it 
occurs only at certain sites. Thus, the extent to which in 
vitro effects produced by the aglycones can be extrapo-
lated to the in vivo situation, in particular in humans, is 
poorly understood (Kroon et al., 2004).
Flavonoids occur in plants mainly in the form of 
O- gl y c o s i d e  c o n j u g a t e s  link e d  t o  s u g ar s  lik e  gl u c o s e ,  
galactose, arabinose or rhamnose (Bravo, 1998; Arts et 
al., 2004). The bioavailability is primarily determined by 
the type of the sugar moiety (Arts et al., 2004; Crozier et 
al., 2010). In the case of flavonoid-O-β-D-glucosides, the 
aglycone can be enzymatically released in the small intes-
tine by the brush border lactase phlorizin hydrolase (Day 
et al., 1998) or by cytosolic β-glucosidase activity (Ioku 
et al., 1998). The enzyme of lactase phlorizin hydrolase 
exhibits broad substrate specificity for flavonoid-mono-
glucosides and the released aglycone may then enter the 
small intestine epithelial cells by passive diffusion (Day et 
al., 2000). Alternatively, cytosolic β-glucosidase functions 
within the epithelial cells after the glucosides entered via 
the sodium-dependent glucose transporter 1(Gee et al., 
2000). On the other hand, e.g. quercetin-3-rutinoside 
(rutin) is not a substrate of lactase phlorizin hydrolase. 
The quercetin aglycone is released hydrolytically by bac-
terial α-rhamnosidases and β-glucosidases in the lower 
gastrointestinal tract. Thus absorption of quercetin from 
rutin is delayed, and quercetin bioavailability is much 
smaller in comparison with that of quercetin-glucosides. 
This example stresses the role of sugar type for bio-
avalability of natural flavonoid glycosides (Hollman et al., 74
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1999; Jaganath et al., 2006; Manach et al., 2005; Crozier 
et al., 2010). Prior to passage into the blood stream, the 
aglycones undergo metabolism forming sulfate, glucuro-
nide and/or methylated metabolites (Morand et al., 1998; 
Manach et al., 2005; Mullen et al., 2006; Crozier et al., 
2010; Kay, 2010). 
Excellent reviews covering broadly the topic of 
bioavalability of flavonoids were published (Scalbert 
& Williamson, 2000; Scalbert et al., 2002; Wale, 2004; 
Clifford, 2004; Manach et al., 2005; Wiliamson & Manach, 
2005; Crozier et al., 2009, 2010; Kay, 2010).
To date, only a few studies have investigated delivery of 
flavonoids to the eye. Drug delivery to the ocular tissues 
depends on the physicochemical and biopharmaceutical 
characteristics of the selected flavonoids and very impor-
tantly on the route of administration. Topical application 
is the most favored mode for ocular conditions. The topi-
cal route is mainly used to deliver drugs to the anterior 
segment of the eye. Local administration may yield much 
higher and effective concentrations of the parent flavo-
noids in the ocular tissues and at much lower doses, than 
the oral route. In the anterior chamber of the eye, the aque-
ous humor bathes the anterior surface of the lens, provid-
ing all oxygen and nutrient requirements. It is therefore 
this route through which dietary flavonoids would reach 
the lens. For example, in the ex vivo experiments reported 
by Cornish et al. (2002), quercetin was shown to enter the 
lens. In the lens, enzymes which metabolized quercetin 
to 3´-O-methyl quercetin were identified. Metabolism 
reduced the efficacy but did not terminate the protective 
action of quercetin since 3´-O-methyl quercetin was also 
found to be effective in reducing opacification. In analogy 
with the ability of fluoroscein glucuronides to enter the 
anterior chamber of the eye following oral administration 
(Grotte et al., 1985), it was hypothesized that quercetin 
glucuronides would also be transported into the aqueous 
humor if present in plasma, where deglucuronidation 
could occur via endogenous β-glucuronidase activity. 
β-Glucuronidase is present in many tissues and body 
fluids in humans (Sperker et al., 1997) and its activity has 
been demonstrated in the normal human lens (Kamei, 
1998) and aqueous humor (Weinreb et al., 1991). Following 
uptake of glucuronides into the aqueous humor, the lens 
could therefore be exposed to the circulating conjugates 
and/or to aglycone following deglucuronidation in the 
aqueous humor. 
Conclusions
Presently, surgical extraction remains the only cataract 
cure. Cataract surgery has become the most frequent 
surgical procedure in people aged 65 years or older in the 
Western world, causing a considerable financial burden 
to the health care system (Head, 2001; Meyer & Sekundo, 
2005; Bockelbrink et al., 2008). Hence, there is an urgent 
n eed  f o r  in expe nsiv e,  n o n - sur gi cal  a p p r oa ch es  to  th e  
treatment of cataract (Olson et al., 2003) since a delay 
of 10 years in the onset of cataract by any means would 
be expected to halve the number of cataract extractions 
(Brian & Taylor, 2001). This calls for a search of alternative 
pharmacological measures to treat this disorder.
In diabetic patients, tight control of hyperglycemia is 
the first prerequisite to attenuate the risk of cataract. In 
addition, adjunct therapy is needed to help preserve vision 
in diabetic patients, aimed at correcting biochemical and 
metabolic abnormalities in the hyperglycemic milieu of 
the diabetic individual. 
The current data on natural polyphenols in relation to 
cataract, along with epidemiological knowledge on diet 
and lens opacity, demonstrate that flavonoids may play a 
role in cataract prevention. Yet future clinical trials are 
needed to assess the benefits of flavonoids in lowering the 
risk of both age-related and diabetic eye complications.
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